UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 26

Sortiert nach

Class I PI3K-mediated Akt and ERK signals play a critical role in FcεRI-induced degranulation in mast cells

International immunology, 2013-04, Vol.25 (4), p.215-220

2013

Link zum Volltext

Verfügbarkeit prüfen

Phase 1 study of DS‐1205c combined with gefitinib for EGFR mutation‐positive non‐small cell lung cancer

Cancer medicine (Malden, MA), 2023-03, Vol.12 (6), p.7090-7104

2023

Link zum Volltext

Verfügbarkeit prüfen

Improvement of Pulmonary Function by Oral Treatment with a VLA-4 Antagonist in a Mouse Asthmatic Model

Journal of Pharmacological Sciences, 2013/02/20, Vol.121(2), pp.172-175

2013

Link zum Volltext

Verfügbarkeit prüfen

Discovery of trans-4-[1-[[2,5-Dichloro-4-(1-methyl-3-indolylcarboxamido)phenyl]acetyl]-(4S)-methoxy-(2S)-pyrrolidinylmethoxy]cyclohexanecarboxylic Acid: An Orally Active, Selective Very Late Antigen-4 Antagonist

Journal of medicinal chemistry, 2009-12, Vol.52 (24), p.7974-7992

2009

Link zum Volltext

Verfügbarkeit prüfen

Identification of trans-4-[1-[[7-fluoro-2-(1-methyl-3-indolyl)-6-benzoxazolyl]acetyl]-(4S)-fluoro-(2S)-pyrrolidinylmethoxy]cyclohexanecarboxylic acid as a potent, orally active VLA-4 antagonist

Bioorganic & medicinal chemistry, 2012-02, Vol.20 (3), p.1201-1212

2012

Link zum Volltext

Verfügbarkeit prüfen

Highly Sensitive Detection Method Reveals Significant Anti-Tumor Activity of Valemetostat in Patients with Relapsed/Refractory Adult T Cell Leukemia

Blood, 2022-11, Vol.140 (Supplement 1), p.9304-9305

2022

Link zum Volltext

Verfügbarkeit prüfen

Synthesis, biological evaluation, and pharmacokinetic study of prolyl-1-piperazinylacetic acid and prolyl-4-piperidinylacetic acid derivatives as VLA-4 antagonists

Bioorganic & medicinal chemistry, 2006-04, Vol.14 (8), p.2725-2746

2006

Link zum Volltext

Verfügbarkeit prüfen

Durable Clinical Impacts and Mechanisms of Action and Resistance in EZH1/2-Targeting Epigenetic Therapy

Blood, 2022-11, Vol.140 (Supplement 1), p.756-757

2022

Link zum Volltext

Verfügbarkeit prüfen

Mechanisms of action and resistance in histone methylation-targeted therapy

Nature (London), 2024-03, Vol.627 (8002), p.221

2024

Link zum Volltext

Verfügbarkeit prüfen

Synthesis and biological evaluation of benzoic acid derivatives as potent, orally active VLA-4 antagonists

Bioorganic & medicinal chemistry, 2007-02, Vol.15 (4), p.1679-1693

2007

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of combination treatment with DS-1205c, an AXL kinase inhibitor, and osimertinib in metastatic or unresectable EGFR-mutant non-small cell lung cancer: results from a multicenter, open-label phase 1 study

Investigational new drugs, 2023-04, Vol.41 (2), p.306-316

2023

Link zum Volltext

Verfügbarkeit prüfen

Identified a morpholinyl-4-piperidinylacetic acid derivative as a potent oral active VLA-4 antagonist

Bioorganic & medicinal chemistry letters, 2005-01, Vol.15 (1), p.41-45

2005

Link zum Volltext

Verfügbarkeit prüfen

4-(Pyrrolidinyl)methoxybenzoic Acid Derivatives as a Potent, Orally Active VLA-4 Antagonist

Chemical and Pharmaceutical Bulletin, 2006, Vol.54(11), pp.1515-1529

2006

Link zum Volltext

Verfügbarkeit prüfen

Class I PI3K-mediated Akt and ERK signals play a critical role in Fc[epsilon]RI-induced degranulation in mast cells

International immunology, 2013-04, Vol.25 (4), p.215-220

2013

Link zum Volltext

Verfügbarkeit prüfen

Investigation of the teratogenic potential of VLA-4 antagonist derivatives in rats

Reproductive toxicology (Elmsford, N.Y.), 2014-11, Vol.49, p.162-170

2014

Link zum Volltext

Verfügbarkeit prüfen

ERK5 is involved in TCR‐induced apoptosis through the modification of Nur77

Genes to cells : devoted to molecular & cellular mechanisms, 2008-05, Vol.13 (5), p.411-419

2008

Link zum Volltext

Verfügbarkeit prüfen

A novel, potent, and orally active VLA-4 antagonist with good aqueous solubility: trans-4-[1-[[2-(5-Fluoro-2-methylphenylamino)-7-fluoro-6-benzoxazolyl]acetyl]-(5S)-[methoxy(methyl)amino]methyl-(2S)-pyrrolidinylmethoxy]cyclohexanecarboxylic acid

Bioorganic & medicinal chemistry, 2013-01, Vol.21 (1), p.42-61

2013

Link zum Volltext

Verfügbarkeit prüfen

cDNA cloning and its pronephros-specific expression of the Wilms' tumor suppressor gene, WT1, from Xenopus laevis

Gene, 1996-10, Vol.175 (1), p.167-172

1996

Link zum Volltext

Verfügbarkeit prüfen

Improvement of Pulmonary Function by Oral Treatment with a VLA-4 Antagonist in a Mouse Asthmatic Model

Journal of Pharmacological Sciences, 2013-02, Vol.121 (2), p.172-175

2013

Link zum Volltext

Verfügbarkeit prüfen

A novel and potent VLA-4 antagonist based on trans-4-substituted cyclohexanecarboxylic acid

Bioorganic & medicinal chemistry, 2009-02, Vol.17 (3), p.1232-1243

2009

Link zum Volltext

Verfügbarkeit prüfen

A novel, potent, and orally active VLA-4 antagonist with good aqueous solubility: trans-4-[1-[[2-(5-Fluoro-2-methylphenylamino)-7-fluoro-6-benzoxazo l yl]acetyl]-(5S)-[methoxy(methyl)amino]methyl-(2S)-pyrrolidinylmeth o x y]cyclohexanecarboxylic acid

Bioorganic & medicinal chemistry, 2013-01, Vol.21 (1), p.42-61

2013

Link zum Volltext

Verfügbarkeit prüfen

Identification of 4-[1-[3-chloro-4-[ N’-(5-fluoro-2-methylphenyl)ureido]phenylacetyl]-(4 S)-fluoro-(2 S)-pyrrolidinylmethoxy]benzoic acid as a potent, orally active VLA-4 antagonist

Bioorganic & medicinal chemistry, 2008-12, Vol.16 (23), p.9991-10000

2008

Link zum Volltext

Verfügbarkeit prüfen

Identification of 4-[1-[3-chloro -4-[N'-(5-fluoro-2-methylphenyl)ureido]phenyl-acetyl]-(4S)-fluoro-(2S)-pyrrolidinylmethoxy]benzoic acid as a potent, orally active VLA-4 antagonist

Bioorganic & medicinal chemistry, 2008-12, Vol.16 (23), p.9991-10000

2008

Link zum Volltext

Verfügbarkeit prüfen

Identification of 4-[1-[3-chloro-4-[N'-(5-fluoro-2-methylphenyl)ureido]pheny lacetyl]-(4S)-fluoro-(2S)-pyrrolidinylmethoxy]benzoic acid as a potent, orally active VLA-4 antagonist

Bioorganic & medicinal chemistry, 2008-12, Vol.16 (23), p.9991-10000

2008

Link zum Volltext

Verfügbarkeit prüfen

Discovery of ans-4-[1-[[2,5-Dichloro-4-(1-methyl-3-indolylcarboxamido)phenyl]acetyl]-(4s)-methoxy-(2S)-pyrrolidinylmethoxy]cyclohexanecarboxylic Acid: An Orally Active, Selective Very Late Antigen-4 Antagonist

Journal of medicinal chemistry, 2009, Vol.52 (24), p.7974-7992

2009

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 26

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(26)
Mit Volltextzugriff
(25)

Publikationsform

Artikel
(26)

Sprache

Englisch
(25)
Japanisch
(8)

Erscheinungsjahr

n.n

Thema

Science & Technology
(16)
Life Sciences & Biomedicine
(15)
Animals
(14)
Integrin Alpha4beta1 - Antagonists & Inhibitors
(11)
Pharmacology & Pharmacy
(11)
Vla-4
(11)
Mice
(10)
Chemistry, Medicinal
(9)
Administration, Oral
(8)
Chemistry
(8)
Physical Sciences
(8)
Chemistry, Organic
(7)
Integrin
(7)
Rats
(7)
Biochemistry & Molecular Biology
(6)
Biological And Medical Sciences
(6)
Humans
(6)
Medical Sciences
(6)
Pharmacology. Drug Treatments
(6)
Structure-Activity Relationship
(6)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Class I PI3K-mediated Akt and ERK signals play a critical role in FcεRI-induced degranulation in mast cells

Phase 1 study of DS‐1205c combined with gefitinib for EGFR mutation‐positive non‐small cell lung cancer

Improvement of Pulmonary Function by Oral Treatment with a VLA-4 Antagonist in a Mouse Asthmatic Model

Discovery of trans-4-[1-[[2,5-Dichloro-4-(1-methyl-3-indolylcarboxamido)phenyl]acetyl]-(4S)-methoxy-(2S)-pyrrolidinylmethoxy]cyclohexanecarboxylic Acid: An Orally Active, Selective Very Late Antigen-4 Antagonist

Identification of trans-4-[1-[[7-fluoro-2-(1-methyl-3-indolyl)-6-benzoxazolyl]acetyl]-(4S)-fluoro-(2S)-pyrrolidinylmethoxy]cyclohexanecarboxylic acid as a potent, orally active VLA-4 antagonist

Highly Sensitive Detection Method Reveals Significant Anti-Tumor Activity of Valemetostat in Patients with Relapsed/Refractory Adult T Cell Leukemia

Synthesis, biological evaluation, and pharmacokinetic study of prolyl-1-piperazinylacetic acid and prolyl-4-piperidinylacetic acid derivatives as VLA-4 antagonists

Durable Clinical Impacts and Mechanisms of Action and Resistance in EZH1/2-Targeting Epigenetic Therapy

Mechanisms of action and resistance in histone methylation-targeted therapy

Synthesis and biological evaluation of benzoic acid derivatives as potent, orally active VLA-4 antagonists

Evaluation of combination treatment with DS-1205c, an AXL kinase inhibitor, and osimertinib in metastatic or unresectable EGFR-mutant non-small cell lung cancer: results from a multicenter, open-label phase 1 study

Identified a morpholinyl-4-piperidinylacetic acid derivative as a potent oral active VLA-4 antagonist

4-(Pyrrolidinyl)methoxybenzoic Acid Derivatives as a Potent, Orally Active VLA-4 Antagonist

Class I PI3K-mediated Akt and ERK signals play a critical role in Fc[epsilon]RI-induced degranulation in mast cells

Investigation of the teratogenic potential of VLA-4 antagonist derivatives in rats

ERK5 is involved in TCR‐induced apoptosis through the modification of Nur77

A novel, potent, and orally active VLA-4 antagonist with good aqueous solubility: trans-4-[1-[[2-(5-Fluoro-2-methylphenylamino)-7-fluoro-6-benzoxazolyl]acetyl]-(5S)-[methoxy(methyl)amino]methyl-(2S)-pyrrolidinylmethoxy]cyclohexanecarboxylic acid

cDNA cloning and its pronephros-specific expression of the Wilms' tumor suppressor gene, WT1, from Xenopus laevis

Improvement of Pulmonary Function by Oral Treatment with a VLA-4 Antagonist in a Mouse Asthmatic Model

A novel and potent VLA-4 antagonist based on trans-4-substituted cyclohexanecarboxylic acid

A novel, potent, and orally active VLA-4 antagonist with good aqueous solubility: trans-4-[1-[[2-(5-Fluoro-2-methylphenylamino)-7-fluoro-6-benzoxazo l yl]acetyl]-(5S)-[methoxy(methyl)amino]methyl-(2S)-pyrrolidinylmeth o x y]cyclohexanecarboxylic acid

Identification of 4-[1-[3-chloro-4-[ N’-(5-fluoro-2-methylphenyl)ureido]phenylacetyl]-(4 S)-fluoro-(2 S)-pyrrolidinylmethoxy]benzoic acid as a potent, orally active VLA-4 antagonist

Identification of 4-[1-[3-chloro -4-[N'-(5-fluoro-2-methylphenyl)ureido]phenyl-acetyl]-(4S)-fluoro-(2S)-pyrrolidinylmethoxy]benzoic acid as a potent, orally active VLA-4 antagonist

Identification of 4-[1-[3-chloro-4-[N'-(5-fluoro-2-methylphenyl)ureido]pheny lacetyl]-(4S)-fluoro-(2S)-pyrrolidinylmethoxy]benzoic acid as a potent, orally active VLA-4 antagonist

Discovery of ans-4-[1-[[2,5-Dichloro-4-(1-methyl-3-indolylcarboxamido)phenyl]acetyl]-(4s)-methoxy-(2S)-pyrrolidinylmethoxy]cyclohexanecarboxylic Acid: An Orally Active, Selective Very Late Antigen-4 Antagonist

Suchergebnisse filtern